1,855 research outputs found

    Synchronizing Sequencing Software to a Live Drummer

    Get PDF
    Copyright 2013 Massachusetts Institute of Technology. MIT allows authors to archive published versions of their articles after an embargo period. The article is available at

    Consumer feedback following participation in a family-based intervention for youth mental health

    Get PDF
    Background. This paper presents findings derived from consumer feedback, following a multicentre randomised controlled trial for adolescent mental health problems and substance misuse. The paper focuses on the implementation of a family-based intervention, including fidelity of delivery, family members’ experiences, and their suggestions for program improvements. Methods. Qualitative and quantitative data

    Epigenetic aging signatures in mice livers are slowed by dwarfism, calorie restriction and rapamycin treatment

    Get PDF
    Background: Global but predictable changes impact the DNA methylome as we age, acting as a type of molecular clock. This clock can be hastened by conditions that decrease lifespan, raising the question of whether it can also be slowed, for example, by conditions that increase lifespan. Mice are particularly appealing organisms for studies of mammalian aging; however, epigenetic clocks have thus far been formulated only in humans. Results: We first examined whether mice and humans experience similar patterns of change in the methylome with age. We found moderate conservation of CpG sites for which methylation is altered with age, with both species showing an increase in methylome disorder during aging. Based on this analysis, we formulated an epigenetic-aging model in mice using the liver methylomes of 107 mice from 0.2 to 26.0 months old. To examine whether epigenetic aging signatures are slowed by longevity-promoting interventions, we analyzed 28 additional methylomes from mice subjected to lifespan-extending conditions, including Prop1df/df dwarfism, calorie restriction or dietary rapamycin. We found that mice treated with these lifespan-extending interventions were significantly younger in epigenetic age than their untreated, wild-type age-matched controls. Conclusions: This study shows that lifespan-extending conditions can slow molecular changes associated with an epigenetic clock in mice livers

    Matter-wave bistability in coupled atom-molecule quantum gases

    Full text link
    We study the matter-wave bistability in coupled atom-molecule quantum gases, in which heteronuclear molecules are created via an interspecies Feshbach resonance involving either two-species Bose or two-species Fermi atoms at zero temperature. We show that the resonant two-channel Bose model is equivalent to the nondegenerate parametric down-conversion in quantum optics, while the corresponding Fermi model can be mapped to a quantum optics model that describes a single-mode laser field interacting with an ensemble of inhomogeneously broadened two-level atoms. Using these analogy and the fact that both models are subject to the Kerr nonlinearity due to the two-body s-wave collisions, we show that under proper conditions, the population in the molecular state in both models can be made to change with the Feshbach detuning in a bistable fashion.Comment: 6 pages, 5 figure

    Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

    Get PDF
    Purpose The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab. Methods Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS. Results A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission. Conclusions To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions
    • 

    corecore